Vilon

Vilon — Thymus / Immune Bioregulator

Vilon is a Khavinson-class short-chain bioregulator peptide that restores youthful gene expression in thymus / immune tissue.

Peptide Specifications

Parameter	Value
Sequence	Lys-Glu
Mass	275.3 g/mol
Purity	>98.0%
Target Organ	Thymus / Immune

Figure 1: Vilon Organ-Specific Bioregulation

Tissue-Specific Mechanism

1. Shortest Khavinson bioregulator — a powerful dipeptide.
2. Stimulates regeneration of thymic epithelial tissue.
3. Reverses age-related thymic involution.
4. Normalizes T-helper to T-suppressor cell ratio.
5. Broad-spectrum immune normalization without autoimmune stimulation.

Figure 2: Thymus / Immune Regeneration Curve

Research Results

• 1: Foundational immune-longevity dipeptide.
• 2: Increases lymphocyte counts and NK cell activity.
• 3: Standalone immune reset for severe immunosuppression.

Thymic Dipeptide Immune Bioregulator

Vilon (Lys-Glu) is the simplest bioregulator in the Khavinson classification—a dipeptide consisting of just two amino acids. Despite this minimal structure, Vilon demonstrates significant immunomodulatory activity by interacting with DNA in thymocyte and T-lymphocyte gene promoters. Vilon is considered the synthetic equivalent of natural thymic peptide extracts, targeting the same immune cell maturation and differentiation pathways as the thymic microenvironment. Its extreme simplicity makes it one of the most cost-effective and well-tolerated bioregulators available.

1. The Lys-Glu dipeptide enters thymocyte nuclei and binds specific DNA sequences in the promoter regions of T-cell differentiation genes.
2. CD4/CD8 T-cell differentiation programs are normalized, restoring the CD4:CD8 ratio that typically inverts with aging.
3. Thymic epithelial cell gene expression is modulated, partially counteracting the thymic involution that reduces naive T-cell output with age.
4. NK cell cytotoxicity gene expression (perforin, granzyme B) is upregulated, enhancing innate immune surveillance.
5. Interferon-gamma production by Th1 cells is normalized, improving antiviral and antitumor immune competence.

Immune Restoration Research

• Immunosenescence: Vilon is the primary bioregulator investigated for age-related immune decline, with the largest body of Khavinson bioregulator clinical data spanning 20+ years.
• Cancer Adjunct: In oncology research, Vilon course administration during and after chemotherapy improved lymphocyte recovery kinetics and reduced infectious complications.
• Simplicity Advantage: As a dipeptide, Vilon has exceptional oral bioavailability, stability, and manufacturing simplicity compared to larger peptide immunomodulators.
• Combination: Commonly combined with Crystagen (thymus bioregulator) and/or Thymosin Alpha-1 for comprehensive immune support protocols.
• Protocol: 1–2 capsules daily for 20–30 days. Courses repeated every 3–6 months, particularly before infection seasons (autumn, winter).